NDA 022563 · Mayne Pharma
Sorilux
Calcipotriene · Topical · Vitamin D Analog
Last checked: Nov 19, 2026Latest source record: Nov 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 6, 2010
Approved uses
4
Original approval plus efficacy supplements
Registered trials
167
41 Phase 3, 8 recruiting
FAERS reports
3,507
1,417 serious, 69 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 9, 2024.
Calcipotriene foam is indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. Calcipotriene foam, is a vitamin D analog indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. ( 1 )
Mechanism: Calcipotriene is a synthetic vitamin D3 analog that has a similar receptor binding affinity as natural vitamin D3. However, the exact mechanism of action contributing to the clinical efficacy in the treatment of psoriasis is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 5, 2019 Supplement 7 · Efficacy LetterPediatric Medical Review
- May 6, 2019 Supplement 6 · Efficacy LabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Sep 27, 2012 Supplement 2 · Efficacy LabelLetter
- Oct 6, 2010 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
- SORILUX · CALCIPOTRIENE 0.005% · AEROSOL, FOAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Calcipotriene" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216827 · 1,485 participants · Start Nov 2004
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel) · For: Psoriasis of Scalp
Sites: Québec, Canada; Roskilde, Denmark; Nice, France · 8 sites in all
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216840 · 1,350 participants · Start Dec 2004
Drug: Calcipotriol plus betamethasone dipropionate (LEO80185 gel) · For: Psoriasis of Scalp
Sites: Leuven, Belgium; Montreal, Canada; Turku, Finland · 7 sites in all
- Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin FoldsPivotal-lookingCompleted
LEO PharmaIndustry
NCT00691002 · 1,245 participants · Start May 2008 · Primary completion Jan 2010
Drug: Calcipotriol plus hydrocortisone (LEO 80190); LEO 80190 Vehicle and 2 more · For: Psoriasis Vulgaris
Sites: Zagreb, Croatia; Bonn, Germany; Warsaw, Poland · 11 sites in all
- LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)Pivotal-lookingCompleted
LEO PharmaIndustry
NCT01188928 · 1,152 participants · Start Sep 2010 · Primary completion Mar 2011
Drug: Calcipotriol plus betamethasone; Betamethasone-17,21-dipropionate and 2 more · For: Psoriasis Vulgaris
Sites: Mobile, Alabama; Hot Springs, Arkansas; Anaheim, California · 59 sites in all
- Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis VulgarisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216892 · 1,032 participants · Start Apr 2005
Drug: Calcipotriol, (calcipotriol + betamethasone) · For: Psoriasis Vulgaris
Sites: Ghent, Belgium; Hamilton, Canada; Saint-Etienne, France · 7 sites in all
- Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese PopulationPivotal-lookingCompleted
LEO PharmaIndustry
NCT02533973 · 951 participants · Start Sep 2015 · Primary completion Mar 6, 2018
Drug: Xamiol® gel; Daivonex® scalp solution · For: Psoriasis Vulgaris
Sites: Hangzhou, China
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp PsoriasisPivotal-lookingCompleted
LEO PharmaIndustry
NCT00216879 · 800 participants · Start Feb 2005
Drug: Calcipotriol plus betamethasone dipropionate gel (LEO 80185) · For: Psoriasis of Scalp
Sites: Moncton, Canada; Hørsholm, Denmark; Saint-Etienne, France · 5 sites in all
- A Clinical Trial Evaluating Efficacy and Safety of MC2-01 CreamPivotal-lookingCompleted
MC2 TherapeuticsIndustry
NCT03308799 · 794 participants · Start Oct 3, 2017 · Primary completion Jun 8, 2018
Drug: MC2-01 cream; Cal/BDP combination and 1 more · For: Psoriasis Vulgaris
Sites: Detroit, Michigan; Fridley, Minnesota; Spokane, Washington
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective843
- psoriasis736
- diarrhoea216
- arthralgia205
- rash197
- nausea190
- pain189
- pruritus184
- off label use179
- headache174
- product use in unapproved indication159
- fatigue150
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 10 |
| 2006 | 12 |
| 2007 | 16 |
| 2008 | 31 |
| 2009 | 21 |
| 2010 | 24 |
| 2011 | 6 |
| 2012 | 29 |
| 2013 | 53 |
| 2014 | 55 |
| 2015 | 136 |
| 2016 | 149 |
| 2017 | 173 |
| 2018 | 185 |
| 2019 | 247 |
| 2020 | 230 |
| 2021 | 230 |
| 2022 | 223 |
| 2023 | 947 |
| 2024 | 256 |
| 2025 | 265 |
| 2026 | 203 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sorilux (Calcipotriene)
2024 spending
$265K
Beneficiaries
80
158 claims
Per beneficiary
$3,314
$13.94 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $855,174 |
| 2021 | $646,478 |
| 2022 | $416,095 |
| 2023 | $350,869 |
| 2024 | $265,110 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
Warren RB, Gold M, Gooderham M, et al. · J Drugs Dermatol 2021 · Clinical Trial, Phase III, Multicenter Study
- Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials.
Gu X, Shen M, Zhao S, et al. · J Dermatolog Treat 2022 · Meta-Analysis, Systematic Review
- Management of Residual Psoriasis in Patients on Biologic Treatment.
Haidari W, Pona A, Feldman SR · J Drugs Dermatol 2020 · Systematic Review
- Topical calcipotriene for morphea/linear scleroderma.
Cunningham BB, Landells ID, Langman C, et al. · J Am Acad Dermatol 1998 · Case Reports, Clinical Trial
- Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Bagel J, Nelson E, Riley C, et al. · J Drugs Dermatol 2020 · Clinical Trial
- Deucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Bagel J, Hetzel A, Reed A, et al. · J Drugs Dermatol 2025 · Clinical Trial
Sponsor: Mayne Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.